Tissue Regenix Group PLC Appointment of Chief Financial Officer (3879M)
January 21 2021 - 2:00AM
UK Regulatory
TIDMTRX
RNS Number : 3879M
Tissue Regenix Group PLC
21 January 2021
Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
Appointment of Chief Financial Officer
Leeds, 21 January 2021 - Tissue Regenix (AIM: TRX), the
regenerative medical devices company, announces that it has
appointed David Cocke as Chief Financial Officer (CFO) and Director
to the Board with immediate effect.
David has over 29 years of experience in the medical device
industry holding senior finance and operations positions. In 1997,
David founded NuPak Medical, an ISO-certified contract manufacturer
of sterile disposable medical devices, with the Company turning
cash flow positive in two years and growing the production volume
from 50k to 3m over time. NuPak Medical was acquired by Katena
Products, Inc. in 2017 and David remained with the business
post-acquisition until early 2021, leading the expansion to double
the clean room capacity and assembly space on-time and on-budget.
David was also Chief Financial Officer at Aperion Biologics from
2008-2017 and supported the Board in raising $21m from venture
capital and private investors. Prior to this, David was Senior
Director for Finance and Operations at Kinetic Concepts from
1993-1996.
Daniel Lee, Chief Executive Officer, Tissue Regenix commented:
"David is a well-respected finance professional in the medical
device industry. His experience of implementing financial systems
and management as well as operations, will be invaluable to the
Group as we undertake the next stages of our capacity expansion
programme. Having worked with David previously at Aperion Biologics
I have seen first-hand the value he brings to a business and I am
happy to welcome him to the Tissue Regenix Group."
Regulatory disclosure - The following information is disclosed
in accordance with Rule 17 and paragraph (g) of Schedule 2 of the
AIM Rules for Companies.
David Claiborne Cocke, 55, holds no ordinary shares in the
Company and no options. David Cocke's current and previous
directorships/partnerships are as follows:
C urrent Directorships / Partnerships Former Directorship / Partnerships
held in the last 5 years:
None NuPak Medical Ltd.
-----------------------------------
Packaging Partners LC
-----------------------------------
Cetus LC
-----------------------------------
Save for the disclosures above, there are no further disclosures
to be made in accordance with Rule 17 and Schedule 2(g) of the AIM
Rules.
For more Information:
Tissue Regenix Group plc Tel: +44 (0)330 430
Caitlin Pearson, Head of Communications 3052
Stifel Nicolaus Europe Limited (Nominated Tel: +44(0)20 7710
Adviser and Broker) 7600
Ben Maddison / Alex Price
Walbrook PR Ltd Tel: +44 (0)20 7933
Paul McManus / Alice Woodings / Lianne 8780
Cawthorne TissueRegenix@walbrookpr.com
About Tissue Regenix ( www.tissueregenix.com )
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human soft tissue leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or worn out body parts. Current
applications address many critical clinical needs such as sports
medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specializes in regenerative
medicine and is dedicated to the development of innovative
osteoinductive and wound care scaffolds that enhance healing
opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general
orthopaedic, foot & ankle, dental, and sports medicine surgical
procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAPPUAPGUPGPGU
(END) Dow Jones Newswires
January 21, 2021 02:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Oct 2023 to Oct 2024